Biocon's Malaysia Insulin Supply Contract Extended By Six Months

Biocon Ltd. on Thursday said the government of Malaysia has extended its insulin supply contract with Biocon Biologics Ltd. and its local subsidiaries by six months. The contract, originally set to end in April 2025, will now run until October 28.

Biocon Biologics, a wholly-owned unit of Biocon, has been supplying insulin to Malaysia’s Ministry of Health for the past 10 years.

The company produces recombinant human insulin at its Johor facility, with distribution handled by commercial partner Duopharma Marketing Sdn. Bhd.

The current supply agreement began in 2022 as a three-year contract and will now continue for an extended term, according to the exchange filing.